HNRNPA1L2

Across TCGA pan-cancer cohorts, HNRNPA1L2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated HNRNPA1L2 data layer compared with 25 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher HNRNPA1L2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated HNRNPA1L2 expression acts as an unfavorable survival marker.

LUSC, PAAD, and ESCA are the cancer types where HNRNPA1L2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	All	0.011	0.776	<.001	36	view →
PAAD	OS	Median	All	0.131	0.613	.001	15	view →
ESCA	DFS	Median	All	0.045	0.533	<.001	12	view →
LUAD	OS	Median	II,III,IV	0.090	0.677	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

HNRNPA1L2–LUSC (OS)

Open the LUSC breakdown →